Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
102M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
61.1M
-
Shares change
-
+997K
-
Total reported value, excl. options
-
$816M
-
Value change
-
-$9.34M
-
Put/Call ratio
-
0.39
-
Number of buys
-
69
-
Number of sells
-
-43
-
Price
-
$13.37
Significant Holders of Day One Biopharmaceuticals, Inc. - COMMON STOCK (DAWN) as of Q1 2023
142 filings reported holding DAWN - Day One Biopharmaceuticals, Inc. - COMMON STOCK as of Q1 2023.
Day One Biopharmaceuticals, Inc. - COMMON STOCK (DAWN) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.1M shares
of 102M outstanding shares and own 59.89% of the company stock.
Largest 10 shareholders include FMR LLC (8.57M shares), Atlas Venture Life Science Advisors, LLC (7.61M shares), RA CAPITAL MANAGEMENT, L.P. (7.04M shares), FRANKLIN RESOURCES INC (3.41M shares), BRAIDWELL LP (3.16M shares), VANGUARD GROUP INC (3.13M shares), Canaan Partners XI LLC (2.55M shares), GOLDMAN SACHS GROUP INC (2.28M shares), BlackRock Inc. (2.26M shares), and STATE STREET CORP (2.26M shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.